Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.30

0.19 (0.53%)

, TEVA

Teva

$6.74

-0.16 (-2.32%)

06:21
10/15/19
10/15
06:21
10/15/19
06:21

Critical chemotherapy drug in short supply, NY Times reports

Vincristine, a critical chemotherapy medication, is in short supply, and physicians say there is no appropriate substitute, The New York Times' Roni Caryn Rabin reports. Dr. Yoram Unguru, a pediatric oncologist at the Herman and Walter Samuelson Children's Hospital at Sinai in Baltimore, told The Times that "Vincristine is our water. It's our bread and butter. I can't think of a disease in childhood cancer that doesn't use vincristine." Shortages of the chemotherapy drug, which is on back order, will likely affect children throughout the country, he said. Pfizer (PFE) is the sole supplier of the drug after Teva (TEVA) made a "business decision to discontinue the drug" in July. "Pfizer has experienced a delay, and we are working closely with them and exploring all options to make sure this critical cancer drug is available for the patients who need it," the FDA said in a brief statement. Reference Link

PFE

Pfizer

$36.30

0.19 (0.53%)

TEVA

Teva

$6.74

-0.16 (-2.32%)

  • 29

    Oct

  • 06

    Nov

  • 07

    Nov

PFE Pfizer
$36.30

0.19 (0.53%)

10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
TEVA Teva
$6.74

-0.16 (-2.32%)

08/08/19
RHCO
08/08/19
NO CHANGE
Target $7
RHCO
Hold
Teva price target lowered to $7 from $10 at SunTrust
SunTrust analyst Gregg Gilbert lowered his price target on Teva to $7 and kept his Hold rating in spite of its Q2 earnings beat. The analyst says the quarter was decent with "continued stability" seen in North America generics, but he is concerned about the perception of the departure of Teva's CEO. Gilbert also points to Teva becoming the first company in his coverage to reserve a sum for potential opioid settlements.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Neutral
Teva assumed with a Neutral at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Teva Pharmaceuticals with a Neutral rating and a $6-$8 fair value range, saying that "expectations for global generics appear right sized." Flanders believes the company should be able to meaningfully address its debt over the next 3-5 years, but noted it will also have to contend with opioid litigation and price collusion litigation that cost $4B-$8B and $1B, respectively. He added that Teva will need to address both its branded pipeline and biosimilars in the medium-term future.
09/30/19
WELS
09/30/19
NO CHANGE
Target $8
WELS
Market Perform
Teva price target lowered to $8 from $17 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Teva to $8 from $17 as he lowered his earnings outlook for 2020 and beyond. The analyst is now including approximately $3 of liability in his valuation that he did not include before. Maris understands how some investors would be buying Teva shares with the idea that the outcome of the opioid and price fixing situations will be more manageable than feared, however he has no particular insight into a potential settlement and continues to have questions as to the timing of the earnings and margin trough. The analyst reiterates a Market Perform rating on the shares.
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.

TODAY'S FREE FLY STORIES

02:55
11/14/19
11/14
02:55
11/14/19
02:55
General news
FX Update: Both the dollar and yen have continued to hold firm »

FX Update: Both the…

01:50
11/14/19
11/14
01:50
11/14/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

01:30
11/14/19
11/14
01:30
11/14/19
01:30
General news
China data misses highlight downside risks »

China data misses…

KDMN

Kadmon

$3.56

-0.155 (-4.18%)

20:59
11/13/19
11/13
20:59
11/13/19
20:59
Syndicate
Kadmon 26M share Spot Secondary priced at $3.40 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

UBER

Uber

$26.70

(0.00%)

20:17
11/13/19
11/13
20:17
11/13/19
20:17
Hot Stocks
Uber chairman buys 35K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

ALPN

Alpine Immune Sciences

$2.49

-0.06 (-2.35%)

19:47
11/13/19
11/13
19:47
11/13/19
19:47
Recommendations
Alpine Immune Sciences analyst commentary at Piper Jaffray »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

19:45
11/13/19
11/13
19:45
11/13/19
19:45
Hot Stocks
HP Inc. raises quarterly dividend to 17.6c from 16.0c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

RETA

Reata Pharmaceuticals

$187.00

4.48 (2.45%)

19:18
11/13/19
11/13
19:18
11/13/19
19:18
Syndicate
Reata Pharmaceuticals 2.4M share Secondary priced at $183.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

BCRX

BioCryst

$1.60

-0.185 (-10.39%)

19:13
11/13/19
11/13
19:13
11/13/19
19:13
Syndicate
BioCryst 37.93M share Secondary priced at $1.45 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

19:03
11/13/19
11/13
19:03
11/13/19
19:03
Periodicals
U.S. lawmaker frustrated with Google's bid to buy Fitbit, Reuters says »

U.S. Representative David…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

FB

Facebook

$193.20

-1.27 (-0.65%)

AMZN

Amazon.com

$1,753.84

-24.49 (-1.38%)

AAPL

Apple

$264.52

2.63 (1.00%)

FIT

Fitbit

$6.86

-0.105 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

, SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

18:51
11/13/19
11/13
18:51
11/13/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ping…

PING

Ping Identity

$16.50

-0.25 (-1.49%)

SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

HI

Hillenbrand

$31.53

-1 (-3.07%)

CPA

Copa Holdings

$107.71

1.89 (1.79%)

PSNL

Personalis

$10.92

0.745 (7.33%)

TRQ

Turquoise Hill

$0.46

-0.006 (-1.29%)

CATS

Catasys

$14.60

-0.47 (-3.12%)

LTRX

Lantronix

$3.15

0.06 (1.94%)

SLGG

Super League Gaming

$3.06

0.07 (2.34%)

BZH

Beazer Homes

$14.67

0.21 (1.45%)

CSCO

Cisco

$48.44

0.06 (0.12%)

TTEK

Tetra Tech

$88.38

1.24 (1.42%)

NTAP

NetApp

$60.04

-0.08 (-0.13%)

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 14

    Nov

BZH

Beazer Homes

$14.67

0.21 (1.45%)

18:49
11/13/19
11/13
18:49
11/13/19
18:49
Earnings
Beazer Homes reports Q4 EPS 8c, two estimates 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HT

Hersha Hospitality

$13.84

-0.23 (-1.63%)

18:46
11/13/19
11/13
18:46
11/13/19
18:46
Hot Stocks
Hersha Hospitality CEO: Airnb has definitely had an impact »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FICO

Fair Isaac

$336.80

2.56 (0.77%)

18:40
11/13/19
11/13
18:40
11/13/19
18:40
Hot Stocks
Fair Isaac director sells 6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

18:33
11/13/19
11/13
18:33
11/13/19
18:33
Hot Stocks
ProPetro discloses U.S. SEC probe »

ProPetro has filed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

DXCM

DexCom

$202.81

-3.35 (-1.63%)

, WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

18:25
11/13/19
11/13
18:25
11/13/19
18:25
Hot Stocks
DexCom CEO: The type 2 diabetes business is just getting started »

In an interview on…

DXCM

DexCom

$202.81

-3.35 (-1.63%)

WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 22

    Nov

EQS

Equus II Inc

$1.55

(0.00%)

18:19
11/13/19
11/13
18:19
11/13/19
18:19
Hot Stocks
Equus reports Q3 NAV per share of $3.63 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSYS

Stratasys

$18.35

-2.39 (-11.52%)

18:04
11/13/19
11/13
18:04
11/13/19
18:04
Recommendations
Stratasys analyst commentary at Piper Jaffray »

Stratasys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GLD

SPDR Gold Shares

$137.98

0.56 (0.41%)

18:03
11/13/19
11/13
18:03
11/13/19
18:03
Hot Stocks
SPDR Gold Shares holdings fall to 896.77MT from 897.09MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

17:57
11/13/19
11/13
17:57
11/13/19
17:57
Hot Stocks
Copa Holdings reports October capacity down 4.8%, traffic down 1.4% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

CCI

Crown Castle

$131.34

0.67 (0.51%)

17:51
11/13/19
11/13
17:51
11/13/19
17:51
Hot Stocks
Crown Castle chairman buys 10.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

17:48
11/13/19
11/13
17:48
11/13/19
17:48
Periodicals
Google confirms several features not available on Stadia at launch, Kotaku says »

During an AMA on Reddit,…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

17:44
11/13/19
11/13
17:44
11/13/19
17:44
Hot Stocks
BAE Systems awarded maximum $270.6M Navy contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.